Drugs / diphtheria-tetanus-acellular pertussis vaccine
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT04054882 Comparator | Aug 2019 → Mar 2020 | — | China National Biotec Group Company Limited | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | diphtheria-tetanus-acellular pertussis vaccine | “The Sabin-strain-based inactivated poliovirus vaccine (sIPV) and the diphtheria-tetanus-acellular pertussis vaccine (DTaP) have been licensed in China for many years.” PMID 35958596 ↗ Jul 2022 |
| Known as | DTaP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04054882 ↗ |